Home / David L. Joffe, BSPharm, CDE, FACA (page 43)

David L. Joffe, BSPharm, CDE, FACA

(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Mechanisms and Receptors Controlling Intestinal GLP-1 Secretion, Part 2

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

Read More »

ADA 2013: Dapagliflozin Update

Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data   The efficacy, tolerability and safety of dapagliflozin was studied compared to glipizide over a period of 4 years. Dapagliflozin is a novel medication that is a highly selective inhibitor of SLGLT2 and reduces …

Read More »

ADA 2013: Empagliflozin Update

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company are working together to pave a new pathway for type 2 diabetes patients with the sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin. The investigational agent is currently in Phase III clinical trials focusing on four pivotal trials that have concluded with …

Read More »

ADA 2013: Canagliflozin Update

Canagliflozin Added on to Dipeptidyl Peptidase-4 Inhibitors or Glucagon-Like Peptide-1 Agonists With or Without Other Antihyperglycemic Agents in Type 2 Diabetes Mellitus (T2DM)   Canagliflozin is an SGLT2 inhibitor which was intended for treatment in diabetic type 2 patients. This analysis was a post hoc design and data was utilized …

Read More »

AACE Presentations of SGLT-2 Inhibitor Data

David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control Lauren Self, University of Florida College of Pharmacy, PharmD Candidate When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it …

Read More »